A Milestone For Accelerated Approval: HIV No Longer Qualifies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is ruling out the accelerated approval pathway for antiretroviral drugs to treat HIV. In a climate where sponsors are eager to expand use of the pathway, that may sound like bad news – it isn’t.